A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00717340
First received: July 16, 2008
Last updated: June 27, 2012
Last verified: June 2012
  Purpose

This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, maximum tolerated dose, and overall response rate of tivozanib (AV-951) and paclitaxel in a breast cancer.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: tivozanib (AV-951) + paclitaxel
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by AVEO Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To determine the safety, tolerability, and maximum tolerated dose (MTD) of tivozanib (AV-951) when administered in combination with paclitaxel (Phase 1b study) [ Time Frame: 4 weeks (1 Cycle) ] [ Designated as safety issue: Yes ]
  • To determine the overall response rate of tivozanib (AV-951) in combination with paclitaxel as a first-line chemotherapy for metastatic breast cancer (Phase 2a study) [ Time Frame: 8 weeks (2 Cycles) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To characterize the pharmacokinetic (PK) profile of tivozanib (AV-951) and paclitaxel when administered in combination (Phase 1b study) [ Time Frame: 8 weeks (2 cycles) ] [ Designated as safety issue: No ]
  • To evaluate the antineoplastic activity of tivozanib (AV-951) and paclitaxel when administered in combination (Phase 1b study) [ Time Frame: 8 weeks (2 Cycles) ] [ Designated as safety issue: No ]
  • To perform an exploratory study in a subset of subjects to evaluate (Phase 1b study): -Changes in FMD during treatment with tivozanib (AV-951) -The relationship between hypertension during tivozanib (AV-951) therapy, FMD and plasma NT levels [ Time Frame: 12 weeks (3 Cycles) ] [ Designated as safety issue: Yes ]
  • To determine the duration of complete and partial responses and time to disease progression (Phase 2a study) [ Time Frame: Not applicable to determine weeks ] [ Designated as safety issue: No ]
  • To determine the safety and tolerability of tivozanib (AV-951) when administered in combination with paclitaxel (Phase 2a study) [ Time Frame: 4 weeks (1 cycle) ] [ Designated as safety issue: Yes ]
  • To evaluate the effect of tivozanib (AV-951) and paclitaxel on global and targeted gene expression patterns (Phase 2a study) [ Time Frame: 8 weeks (2 Cycles) ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: February 2009
Study Completion Date: February 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: tivozanib (AV-951) + paclitaxel Drug: tivozanib (AV-951) + paclitaxel

Tivozanib (AV-951):

Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.

Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.

Paclitaxel: Phase 1b study and Phase 2a study:

All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks).


Detailed Description:

This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, maximum tolerated dose, and overall response rate of tivozanib (AV-951) and paclitaxel in a breast cancer.

In the Phase 1b study, only the doses of tivozanib (AV-951) will be escalated from 0.5 mg/day to 1.5 mg /day. All subjects will receive doses of weekly paclitaxel chemotherapy.

The Phase 2a study portion of the study was not conducted.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ≥ 18-year-old females
  2. Histologically or cytologically documented invasive breast cancer
  3. Documented progressive disease (Phase 1b study) OR documented metastatic disease (Phase 2a study)
  4. Prior Treatment:

    • Phase 1b study: No more than 4 prior chemotherapy treatments, only 1 prior taxane-based regimen for metastatic disease. There is no limit to the number of prior hormonal or biological treatments.
    • Phaes 2a study: No prior chemotherapy or biological therapy for metastatic breast cancer. There is no limit to the number of prior hormonal treatments.
    • Prior adjuvant chemotherapy or biological therapy will not be counted in the number of prior treatments, unless recurrence occurs within 12 months of last dose of adjuvant therapy, in which case it will be counted as 1 prior therapy; adjuvant treatment with a taxane is allowed.
  5. Measurable or evaluable disease by RECIST criteria (Phase 1b study) (see Appendix A). Subjects to be enrolled in the Phase 2a study are required to have measureable disease according to RECIST.
  6. No prior VEGF-TKI drugs such as sunitinib, sorafenib, AZ2171, AG013736, GW786034, ZD6474 AMG706, PTK/ZK and other similar agents.
  7. No treatment with bevacizumab within 4 weeks prior to start of protocol therapy, no prior treatment with other VEGF binding antibodies or VEGF-trap.
  8. No treatment with the following agents within 3 weeks prior to start of protocol therapy:

    • Chemotherapy (at least 6 weeks for nitrosoureas, mitomycin C, and liposomal doxorubicin)
    • Other signal transduction inhibitors and monoclonal antibodies
    • Immunotherapy or biological response modifiers
    • Any experimental therapy
  9. No treatment with radiotherapy within 2 weeks (if involving < 25% of bone marrow), or 4 weeks (if involving ≥ 25% of bone marrow) prior to start of protocol therapy.
  10. Resolution of all toxicities
  11. ECOG performance status ≤ 2 and life expectancy ≥ 3 months.
  12. Signed and dated written informed consent

Exclusion Criteria:

  1. Known hypersensitivity to paclitaxel or to any other component of the paclitaxel formulation
  2. Pregnant or lactating women; all fertile subjects must use effective contraception (barrier method) while on study and for 3 months thereafter. All subjects must agree to use a highly effective method of contraception (including their partner). Effective birth control includes (a) IUD plus 1 barrier method, or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm.) Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.
  3. Subjects with symptomatic CNS metastases. Subjects with treated brain metastases that have remained stable for at least 3 months without steroids are allowed. Subjects with signs or symptoms or history of brain metastasis must have a CT or MRI scan of the brain within 1 month prior to the start of protocol therapy. Subjects with spinal cord or nerve root compression who have completed treatment at least 4 weeks before the start of protocol therapy and are stable without steroid treatment for at least one week before start of protocol therapy are allowed. Subjects with leptomeningeal metastases are not allowed.
  4. Any of the following hematologic abnormalities:

    • Hemoglobin < 9.0 g/dL
    • ANC < 1500 per mm3
    • Platelet count < 100,000 per mm3
  5. Any of the following serum chemistry abnormalities:

    • Total bilirubin > 1.5 × ULN (>2.5 mg/dL in patients with Gilbert's syndrome)
    • AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)
    • GGT > 2.5 x ULN (or > 5 × ULN for subjects with liver metastasis)
    • Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis)
    • Serum albumin < 3.0 g/dL
    • Serum creatinine > 1.5 × ULN
    • Proteinuria > 2.5 g/24 hours or 3+ with urine dipstick
    • Any other ≥ Grade 3 laboratory abnormality at baseline (other than those listed above)
  6. Significant cardiovascular disease, including:

    • Clinically symptomatic heart failure. Subjects with a history of heart failure must have an ECHO or MUGA scan to document left ventricular ejection fraction (LVEF) > 45% prior to start of protocol therapy
    • Uncontrolled hypertension: Blood pressure >140/90 mm Hg on more than 2 antihypertensive medications, on two consecutive measurements obtained at least 24 hours apart. Subjects with a history of hypertension must have been on stable doses of anti-hypertensive drugs for ≥ 2 weeks prior to start of protocol therapy.
    • Myocardial infarction within 3 months prior to start of protocol therapy
  7. Baseline neuropathy > Grade 1
  8. Subjects with delayed healing of wounds, ulcers, and/or bone fractures
  9. Serious/active infection or infection requiring parenteral antibiotics
  10. Inadequate recovery from any prior surgical procedure; major surgical procedure within 6 weeks prior to start of protocol therapy.
  11. Inability to comply with protocol requirements
  12. Ongoing hemoptysis or history of clinically significant bleeding within 6 months prior to start of protocol therapy
  13. Cerebrovascular accident within 12 months to start of protocol therapy, or peripheral vascular disease with claudication on walking less than 1 block.
  14. Deep venous thrombosis or pulmonary embolus within 6 months prior to start of protocol therapy
  15. Subjects with a "currently active" second primary malignancy other than non-melanoma skin cancers. Subjects are not considered to have a "currently active" malignancy if they have completed anti-cancer therapy and have been disease free for > 2 years.
  16. Known concomitant genetic or acquired immune suppression disease such as HIV
  17. Treatment with systemic hormonal therapy within 3 weeks prior to start of or during protocol therapy, with the exception of:

    • Hormonal therapy for appetite stimulation or contraception
    • Nasal, ophthalmic, inhaled and topical steroid preparations
    • Oral replacement therapy for adrenal insufficiency
    • Low-dose maintenance steroid therapy (equivalent of prednisone 10mg/day) for other conditions
    • Hormone replacement therapy
  18. Herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components) or CYP3A4 inhibitors within 2 weeks prior to start of or during protocol therapy.
  19. Full dose oral anticoagulation with warfarin, acenocoumarol, fenprocoumon, or similar agents. If previously receiving these type of agents, a minimum washout of 1 week and documented INR < 1.5 x ULN will be required prior to start of protocol therapy. Full dose anti-coagulation with low molecular weight heparin or unfractionated heparin administered subcutaneously is allowed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00717340

Locations
United States, Massachusetts
Dana Farber Cancer Institute, Inc.
Boston, Massachusetts, United States, 02115
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Germany
Universitaetsklinikum Essen
Essen, Germany, D-45147
Sponsors and Collaborators
AVEO Pharmaceuticals, Inc.
Investigators
Study Director: Joshua Zhang, M.D. AVEO Pharmaceuticals, Inc.
Principal Investigator: Erica Mayer, M.D. Dana Farber Cancer Institute, Inc.
Principal Investigator: Max E. Scheulen, M.D. Universitaetsklinikum Essen, Germany
Principal Investigator: Maura Dickler, M.D. Memorial Sloan-Kettering Cancer Center
  More Information

No publications provided

Responsible Party: AVEO Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00717340     History of Changes
Other Study ID Numbers: AV-951-08-104
Study First Received: July 16, 2008
Last Updated: June 27, 2012
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AVEO Pharmaceuticals, Inc.:
tivozanib
AV-951

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 01, 2014